News & Updates

The interim analysis of the AMPLIFY trial provides the first phase III evidence of fixed-duration therapy combining a second-generation Bruton tyrosine kinase inhibitor (BTKi) with venetoclax with or without anti-CD20 for treatment-naïve (TN) chronic lymphocytic leukaemia (CLL).

The first phase III trial of pirtobrutinib in haematologic malignancies to readout has demonstrated superiority over investigator's choice in delaying progression in pretreated chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL), with results from the BRUIN CLL-321 study first presented at ASH 2024.

A recent study at Singapore General Hospital has noted no change in the volume of hip fractures during the COVID-19 pandemic, but patients admitted during this period appear to be more “deconditioned.”

In the 7-year update of the phase III ALESIA trial, alectinib outdoes crizotinib for Asian patients with treatment-naïve, advanced or metastatic ALK+ non-small-cell lung cancer (NSCLC).